| Today's Big NewsJun 6, 2023 |
|
Wednesday, Jun 14, 2023 | 10:00am ET / 7:00am PT Targeting proteins for degradation therapeutically, as an alternative to inhibiting them, holds great promise for treating diseases in which pathogenic proteins are considered "undruggable" due to a lack of active sites for conventional small molecules. Register now. 
|
|
| By Gabrielle Masson As usual, ASCO occurred the first weekend in June in Chicago. Except this year, a superstar whose reputation precedes her put on a rivaling show right next door. |
|
|
|
| San Diego, CA |  |
|
|
By Kevin Dunleavy Alkermes has bumped up its revenue forecast for 2023 by $425 million after winning a final award in its arbitration battle with Johnson & Johnson over the licensing of its NanoCrystal technology. The final award came last week from the arbitral tribunal. |
By Andrea Park Study results that Novocure presented at the American Society of Clinical Oncology annual meeting Tuesday scratched a seven-year itch: According to the company, it's the first phase 3 clinical trial in at least as long to detail a therapy’s ability to significantly improve the survival rate for patients with platinum-resistant, metastatic non-small cell lung cancer. |
By Max Bayer Caribou Biosciences doesn't want to follow the leader as its cell therapy rival backs off to focus on relapsed patients with lymphoma. Instead, CEO Rachel Haurwitz, Ph.D., says the CRISPR-focused company is looking a few plays ahead. |
|
Thursday, June 15, 2023 | 11am ET / 8am PT In this era of personalized medicine, biomarkers can provide important insights at every stage of drug discovery and development. By advancing our understanding of cancer pathophysiology and tumor profiling, they play a critical role in the rational development of novel therapies. Register now to learn more. 
|
|
By Eric Sagonowsky As GSK and Pfizer look to roll out their adult RSV vaccines later this year, Sanofi and AstraZeneca hope to join them on the market with an antibody designed to protect infants. But first the partners will need to pass several regulatory milestones, including an FDA advisory committee discussion set for later this week. |
By Andrea Park Hundreds of people who used Grail’s Galleri multicancer blood test reportedly received letters last month incorrectly indicating that they might have cancer. |
By Andrea Park Abiomed has begun a recall of several hundred of its Impella heart pumps after receiving nearly 200 complaints, and the FDA this week gave it a Class I rating, indicating a heightened risk of injury or death. |
By Eric Sagonowsky The pharma industry has voiced loud complaints about the Biden administration's Inflation Reduction Act, specifically focusing on a clause that will allow Medicare to negotiate the prices of top-selling pharmaceuticals. But now the industry is taking its arguments to the courts. |
By Max Bayer “It's a good time to be investing in and acquiring innovation,” Jazz Pharmaceuticals CEO Bruce Cozadd says, as the company scouts for deals at the BIO International Convention. |
By Zoey Becker Eisai was the victim of a ransomware attack late Saturday night and is now working on response efforts, including the creation of a company-wide task force. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the need to democratize access to medications like emergency contraception, plus Elizabeth Holmes, the state of Alzheimer's research, and the rest of the week's headlines. |
|
|---|
|
|
|
Tuesday, June 27, 2023 | 2:00pm ET / 11:00am PT In this webinar we will discuss the growing complexity of clinical research, examples of how eClinical tools can reduce human effort, streamlining the time to approval, current challenges and gaps in eClinical tech, and more. Register now. 
|
|
Whitepaper Autoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
eBook See how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
Whitepaper This paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper ChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
